Virtual Event Showcases CyTOF Technology and Its Use in High-Parameter Suspension Mass Cytometry and Imaging Mass Cytometry

Leading Academic and Pharma Researchers Detail Latest CyTOF Based Discoveries in Infectious Disease, Immunology and the Tumor Microenvironment

SOUTH SAN FRANCISCO, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the agenda for the 9th Annual Fluidigm Mass Cytometry Summit on September 23. The full-day, virtual event showcases CyTOF^® technology and its use in high-parameter suspension mass cytometry and Imaging Mass Cytometry™.

Each year, the Mass Cytometry Summit underscores the significant role that mass cytometry plays in immunology, immune function, immuno-oncology and infectious disease, including discovery of important new biomarkers. Presentations by leading translational and clinical researchers from major academic institutions and pharmaceutical companies detail work using CyTOF technology to uncover new insights across a range of diseases. The 2020 Summit emphasizes the latest CyTOF based discoveries in infectious disease, immunology and the tumor microenvironment.

“The annual Summit provides a unique forum for customers who are making meaningful contributions across all of life science, solving some of the most complex challenges in translational and clinical research,” said Chris Linthwaite, President and CEO. “Researchers using the powerful capabilities of our CyTOF technology are at the forefront of discovery of new biomarkers for disease insight and treatment, evidenced by its use in more than 100 clinical research trials and over 1,000 peer-reviewed publications. Increasingly, this technology is proving critical in exploring immune response to infection and in vaccine development as researchers grapple with the COVID-19 global health crisis.”

The 2020 Summit will include presentations detailing new and unique applications for CyTOF systems that enhance and simplify large, multi-site translational and clinical research studies in immunology and infectious disease. These include live-cell barcoding for sample multiplexing, which enables larger studies and reduces sample-to-sample variability; infectious disease-tailored expansion panels for the company’s popular Maxpar^® Direct™ Immune Profiling Assay™; and the improved Maxpar Panel Designer v2.0. The event will also highlight Fluidigm^® Therapeutic Insights Services, designed to provide broader researcher access to mass cytometry and Imaging Mass Cytometry (IMC™).

Notable presenters include:

• Rebecca Ihrie, PhD, Associate Professor of Cell and Developmental Biology, Vanderbilt University (Keynote)
• Marcelo Sztein, MD, Professor of Pediatrics, Associate Director for Basic and Translational Research, Immunology Group Leader, Center for Vaccine Development and Global Health, University of Maryland (Keynote)
• Bernd Bodenmiller, PhD, Professor for Quantitative Biology, Department of Quantitative Biomedicine, University of Zurich
• Jared K. Burks, PhD, Associate Professor, Co-Director, Flow Cytometry and Cellular Imaging Core Facility, University of Texas MD Anderson Cancer Center
• Kara L. Davis, DO, Assistant Professor of Pediatrics, Maternal & Child Health Research Institute, Stanford University
• Melissa Davis, PhD, Assistant Professor of Cell and Developmental Biology, Weill Cornell Medical College
• Raphael Gottardo, PhD, J. Orin Edson Foundation Endowed Chair, Scientific Director, Translational Data Science Integrated Research Center, Fred Hutchinson Cancer Research Center
• Won Jin Ho, MD, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Philip Hobson, PhD, Deputy Head of Flow Cytometry, The Francis Crick Institute
• Amir Horowitz, PhD, Assistant Professor of Oncological Sciences, Precision Immunology Institute/Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
• Akil Merchant, MD, Associate Professor and Director of Imaging Mass Cytometry Shared Resource, Cedars-Sinai Medical Center
• Handan Xiang, PhD, Senior Scientist, Merck Research Laboratories

Registration
The Annual Mass Cytometry Summit is an international meeting of the mass cytometry community designed for both new and experienced users, as well as those simply interested in learning more about CyTOF technology and its use in high-parameter cytometry (suspension mass cytometry) and IMC. In addition to major presentations, there will be plenary sessions covering multiple applications, special-topic breakout sessions and tutorials. Register here.

About Fluidigm
Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF^® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.

Fluidigm, the Fluidigm logo, CyTOF, Direct, Imaging Mass Cytometry, IMC, Immune Profiling Assay, and Maxpar are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Forward-Looking Statements for Fluidigm
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding research applications for mass cytometry and the potential benefits of Fluidigm products for such research. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2019, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.

Available Information
We use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.

Fluidigm

Media:
Mark Spearman
Senior Director, Corporate Communications
650 243 6621
mark.spearman@fluidigm.com

Investors:
Agnes Lee
Vice President, Investor Relations
650 416 7423
agnes.lee@fluidigm.com